![](https://i.imgur.com/CLvY2jA.png")
27-01-2023, 09:42 AM
Members of the panel were also supportive of the FDA’s plan to move to a single annual vaccine dose for most Americans, which will be matched annually to circulating strains of the SARS-CoV-2 virus.
For older people, immunocompromised individuals, and young children, two doses would be given, according to FDA plans.
However, little data was presented on the risk of myocarditis, a rare side effect of the vaccine that shows up mainly in men and adolescent boys.
The panelists did seem to believe that the idea of another annual shot, at least next year, was warranted by the current data.
But several panelists hoped that a better vaccine would emerge over time, though it’s not clear how a new vaccine would be developed.
https://www.statnews.com/2023/01/26/fda-...mpaign=rss
For older people, immunocompromised individuals, and young children, two doses would be given, according to FDA plans.
However, little data was presented on the risk of myocarditis, a rare side effect of the vaccine that shows up mainly in men and adolescent boys.
The panelists did seem to believe that the idea of another annual shot, at least next year, was warranted by the current data.
But several panelists hoped that a better vaccine would emerge over time, though it’s not clear how a new vaccine would be developed.
https://www.statnews.com/2023/01/26/fda-...mpaign=rss
